{"id":1164861,"date":"2026-08-23T13:37:14","date_gmt":"2026-08-23T13:37:14","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1164861\/"},"modified":"2026-08-23T13:37:14","modified_gmt":"2026-08-23T13:37:14","slug":"johnson-johnson-jnj-wins-eu-approval-for-tecvayli-combo-in-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1164861\/","title":{"rendered":"Johnson &#038; Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/simplywall.st\/features\/community-narratives?utm_medium=finance_user&amp;utm_campaign=community_head_cta&amp;utm_source=yahoo&amp;blueprint=4722748\" data-ylk=\"slk:Get%20insights%20on%20thousands%20of%20stocks;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Get insights on thousands of stocks&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St.  <\/p>\n<ul class=\"yf-1jsc1up\">\n<li class=\"yf-1jsc1up\">\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Johnson &amp; Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI\u00ae\u25bc (teclistamab) plus daratumumab for adults with relapsed or refractory multiple myeloma.  <\/p>\n<\/li>\n<li class=\"yf-1jsc1up\">\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The decision allows use of the combination as early as second line for patients whose disease has returned or is not responding to prior treatment.  <\/p>\n<\/li>\n<li class=\"yf-1jsc1up\">\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The approval is based on Phase 3 data that showed material improvements in patient outcomes versus existing standards of care.  <\/p>\n<\/li>\n<li class=\"yf-1jsc1up\">\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This adds another immunotherapy option to Johnson &amp; Johnson&#8217;s oncology portfolio in Europe within hematology.  <\/p>\n<\/li>\n<\/ul>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Consider broadening your research across other healthcare and immunotherapy stocks through <a href=\"https:\/\/simplywall.st\/discover\/investing-ideas\/434426\/healthcare-ai\/us?utm_medium=finance_user&amp;utm_campaign=cta_screener_healthcare_ai&amp;utm_source=yahoo&amp;blueprint=4722748\" data-ylk=\"slk:40%20healthcare%20AI%20stocks;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;40 healthcare AI stocks&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">40 healthcare AI stocks<\/a>.  <\/p>\n<p>    <a href=\"https:\/\/www.simplywall.st\/company\/id\/f8f92af2-8452-4ce8-b374-906eb8af2a37?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"NYSE:JNJ Earnings &amp; Revenue Growth as at Aug 2026\" height=\"613\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> NYSE:JNJ Earnings &amp; Revenue Growth as at Aug 2026           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Johnson &amp; Johnson is a US based pharmaceuticals company that develops and sells a wide range of healthcare products worldwide, so the addition of this multiple myeloma regimen fits within its broader efforts in oncology. With a market cap of about US$651.3b, the company has the scale to support late stage drug development and commercial rollout.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.simplywall.st\/company\/id\/f8f92af2-8452-4ce8-b374-906eb8af2a37?utm_medium=finance_user&amp;utm_campaign=cta_news_full_picture&amp;utm_source=yahoo\" data-ylk=\"slk:Beyond%20the%20headline%3A%201%20risk%20and%202%20things%20going%20right%20for%20Johnson%20%26%20Johnson%20that%20every%20investor%20should%20see.;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Beyond the headline: 1 risk and 2 things going right for Johnson &amp; Johnson that every investor should see.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Beyond the headline: 1 risk and 2 things going right for Johnson &amp; Johnson that every investor should see.<\/a>  <\/p>\n<p>        Multiple myeloma approval links directly to Johnson &amp; Johnson&#8217;s oncology growth catalyst          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This European Commission decision ties closely to the Johnson &amp; Johnson Narrative that expects a larger contribution from oncology and immunology to help offset loss of exclusivity on older drugs such as STELARA. TECVAYLI plus daratumumab aligns with the catalyst that next generation therapies can support revenue in the Innovative Medicine segment, which analysts already factor into expectations for higher revenue and profit margins through 2029. It also partially tests the risk that competition and policy pressure could weigh on established products, since broader myeloma use may help diversify the portfolio away from single drug dependencies.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">If we take a look at the <a href=\"https:\/\/simplywall.st\/narratives\/xp68n3qa-analyst-commentary-drives-higher-valuation-targets-for-johnson-and-johnson-amid-positive-company-developments?utm_medium=finance_user&amp;utm_campaign=cta_news_narrative_inline&amp;utm_source=yahoo&amp;blueprint=4722748\" data-ylk=\"slk:community%20Narrative%20for%20Johnson%20%26%20Johnson;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;community Narrative for Johnson &amp; Johnson&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">community Narrative for Johnson &amp; Johnson<\/a>, we can see how this news fits into the bigger investment story.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The practical proof point to watch from here is uptake of the TECVAYLI plus daratumumab regimen in Europe over the next few years, including how often it is used in earlier lines of treatment and how that shows up in Johnson &amp; Johnson&#8217;s reported oncology and immunology revenue mix in coming annual results.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">For the full picture including more risks and rewards, check out the <a href=\"https:\/\/www.simplywall.st\/company\/id\/f8f92af2-8452-4ce8-b374-906eb8af2a37?utm_medium=finance_user&amp;utm_campaign=cta_news_deeper_analysis&amp;utm_source=yahoo\" data-ylk=\"slk:complete%20Johnson%20%26%20Johnson%20analysis;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;complete Johnson &amp; Johnson analysis&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">complete Johnson &amp; Johnson analysis<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.<\/strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Companies discussed in this article include <a href=\"https:\/\/finance.yahoo.com\/quote\/JNJ\" data-ylk=\"slk:JNJ;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;JNJ&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">JNJ<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><strong>Have feedback on this article? Concerned about the content? <\/strong><a href=\"https:\/\/investor-research.typeform.com\/to\/wvg6MFri#feedback_token=NDcyMjc0ODo1MGYyMjFhYjg5NGYyYTIy&amp;company=NYSE:JNJ&amp;blueprintid=4722748\" data-ylk=\"slk:Get%20in%20touch;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Get in touch&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><strong>Get in touch<\/strong><\/a><strong> with us directly.<\/strong> Alternatively, email <a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/mailto:editorial-team@simplywallst.com?subject=Re%3A%20Your%20article%20on%20NYSE%3AJNJ%20(yahoo)%20from%2023rd%20August%202026\" data-ylk=\"slk:editorial-team%40simplywallst.com;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;editorial-team@simplywallst.com&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">editorial-team@simplywallst.com<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply&hellip;\n","protected":false},"author":2,"featured_media":1164862,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[5174],"tags":[2000,299,5187,4835,135118],"class_list":["post-1164861","post","type-post","status-publish","format-standard","has-post-thumbnail","category-eu","tag-eu","tag-europe","tag-european","tag-johnson-johnson","tag-multiple-myeloma"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117145098129959099","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1164861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1164861"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1164861\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1164862"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1164861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1164861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1164861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}